About this trial
In this study researchers are testing GSK5764227, a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancers ability to grow and spread. This study specifically aims to evaluate how well GSK5764227 works in treating relapsed Small Cell Lung Cancer compared to standard treatment topotecan, by checking whether GSK5764227 makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether GSK576227 is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving GSK5764227 and the other receiving topotecan. Topotecan is a current standard treatment for SCLC after patients’ cancer has not improved or has gotten worse after previous chemotherapy for SLCL.
Patients who are eligible to participate on this study will be assigned by chance (one chance in two) to one of two treatment groups via a process called randomization. Patients assigned to treatment group one will receive GSK5764227. Patients assigned to treatment group two will receive SoC Topotecan which will be the ‘control group’. Patients will be asked to visit the study doctor for study treatment either GSK5764227 or Topotecan by infusion every 3 weeks for 3 cycles (each cycle is 21 days), as long as their cancer is not getting worse or they do not have serious side effects. About 300 people will be in the study in total.
Patient Profile
Relapsed Small Cell Lung Cancer (SCLC)
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | GSK 223674 |
|---|---|
| Number: | 26-02 |
| Full Title: | Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC) |
| Principal Investigator: | Prof Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | GSK |
| Recruitment Started: |
Global: Ireland: Feb-26 |
| Global Recruitment Target: | 300 |
|---|---|
| Ireland Recruitment Target: | 3 |